Scutellarin Attenuates the IL-1β-Induced Inflammation in Mouse Chondrocytes and Prevents Osteoarthritic Progression

Area of Science:

• Biochemistry
• Pharmacology
• Biomedical Engineering

Background:

• Osteoarthritis (OA) is a degenerative joint disease characterized by cartilage inflammation and breakdown.
• Scutellarin (SCU), a flavonoid glycoside, possesses known anti-inflammatory properties.
• The therapeutic potential of SCU in OA progression remains unexplored.

Purpose of the Study:

• To investigate the impact of Scutellarin (SCU) on osteoarthritis (OA) progression in a murine model.
• To evaluate SCU's effects on key molecular markers of cartilage degradation and inflammation in chondrocytes.
• To assess SCU's therapeutic efficacy in vivo using a destabilization of the medial meniscus (DMM) OA model.

Main Methods:

• In vitro analysis of murine chondrocytes using qRT-PCR and Western blotting to measure expression of MMP-13, ADAMTS-5, COX-2, iNOS, IL-6, TNF-α, and PGE2.
• In vivo assessment using a destabilization of the medial meniscus (DMM) murine model of OA.
• Evaluation of SCU's impact on aggrecan and collagen II degradation, and NF-κB and Nrf2 signaling pathways.

Main Results:

• SCU significantly inhibited the expression of OA-associated factors including MMP-13, ADAMTS-5, COX-2, and iNOS in chondrocytes.
• SCU suppressed the IL-1β-induced overproduction of IL-6, TNF-α, and PGE2 in a concentration-dependent manner.
• SCU reversed aggrecan and collagen II degradation and modulated NF-κB and Nrf2 signaling pathways in both in vitro and in vivo OA models.

Conclusions:

• Scutellarin (SCU) demonstrates significant anti-inflammatory and chondroprotective effects in OA models.
• SCU effectively inhibits key molecular pathways involved in OA pathogenesis.
• SCU shows promise as a potential therapeutic agent for treating osteoarthritis.